Resverlogix Corp.

Resverlogix Corp. is developing RVX-208, a first-in-class, small molecule selective BET bromodomain inhibitor for the potential treatment of patients with cardiovascular disease, diabetes mellitus, Alzheimer's disease, peripheral artery disease and chronic kidney disease. RVX-208 is the only selective BET bromodomain inhibitor in clinical trials. The company's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. Resverlogix can be followed on its blog at http://www.resverlogix.com/blog and via Twitter https://twitter.com/resverlogix_rvx @Resverlogix_RVX

Expert Comments:

Management Q&A: View From the Top
Donald McCaffrey
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug candidate has demonstrated its ability to significantly reduce major adverse cardiac events in three consecutive clinical trials. That, company President and CEO Donald McCaffrey tells The Life Sciences Report, is why RVX-208 will likely be a blockbuster.
read more >
Dan Trang, Stonegate Capital Partners (8/17/15)
"Resverlogix Corp. attained Phase 3 status for its BETonMACE trial and is set to begin in fall 2015. . .the trial will be held at over 40 European and possible U.S. sites with a 1,500–2,500 patient minimum, and its primary endpoint is to show major adverse cardiac events reduction of 20%."

"Resverlogix Corp. is a name I think investors should put on the radar. The company will enroll the first patient in its all-important BETonMACE Phase 3 clinical trial with RVX-208 in the Q4/15. RVX-208 is a first-in-class selective bromodomain and extra-terminal domain (BET) antagonist designed to reduce the incidence of major adverse cardiac events (MACE) in high-risk patients with diabetes mellitus and low HDL cholesterol. Previous data with RVX-208 showed the drug reduced incidents of MACE in this high-risk population, as well as conferred a benefit to patients with chronic kidney disease and elevated c-reative protein. We are intrigued by Resverlogix because of the targeted nature of RVX-208, based on all the company has learned from previous Phase 2 clinical studies. Resverlogix is now well capitalized, and since it is going after an area where big pharma has clearly shown an interest, we think that if results from the BETonMACE Phase 3 program are positive, the stock could have a significant revaluation to much higher levels." read more >

"Resverlogix Corp. is active in targeting cardiovascular disease. It has a proprietary drug development platform that's based on targeting bromodomain and extra terminal (BET) domain proteins. BET proteins have potential in many diseases, including cardiovascular disease, neurodegenerative disease and diabetes. BET bromodomain inhibition is an epigenetic mechanism that can turn disease-causing genes off, returning them to a healthier state. . .using epigenetics (to target cardiovascular disease) is getting more emphasis from scientists and cardio specialists. The approach being developed by Resverlogix is a small molecule that can uncover the involved environmental and individual aspects of lifestyle that directly interact with the genome to influence epigenetic change in the DNA of a person. The company is targeting patients who have diabetes mellitus or chronic kidney failure who are at high risk for cardiovascular disease. . .the company may have the answer to developing a new generation of cardio drugs. . ." read more >

Jason Napodano, Zacks Equity Research (4/20/15)
"Resverlogix Corp. is addressing the major problem of the unmet need in cardiovascular management. . .while the majority of current therapies aim to manage glucose levels in diabetic patients, the company is taking a unique approach by looking at it from the point of view of reducing Major Adverse Cardiac Events (MACE)—the primary killer in both men and women. . .furthermore, chronic kidney disease is an extension of diabetes and also results in high cardiovascular disease death rates, which Resverlogix is also looking to solve."

Bjarke Krysel Christensen, Seeking Alpha (4/8/15)
"The pooled results from two recent Phase 2 clinical trials with Resverlogix Corp.'s RVX-208 indicated that treatment resulted in a drastic and statistically significant reduction of major adverse cardiac events in a patient population with established atherosclerosis. . .a subgroup analysis of patients who were given RVX-208 in combination with AstraZeneca's Crestor showed a statistically significant degree of plaque regression. . .keeping in mind that these promising results and the results from the diabetes mellitus subpopulation of patients were the result of a post hoc analysis, there has to be a very compelling explanation rooted in RVX-208's mode of action for anyone to make an investment in Resverlogix."

Dan Trang, Stonegate Capital Partners (4/1/15)
"Resverlogix Corp. expects to start its trial that should validate RVX-208's safety profile. If the results are positive, it could be promising for its commercialization efforts and could also expand to other indications beyond diabetes. . .the company is uniquely positioned to leverage its novel molecule, RVX-208, in cardiovascular disease, particularly atherosclerosis, and hopefully later in Alzheimer’s disease and diabetes."

More Expert Comments

Experts Following This Company

Jason Napodano, Managing Director and Senior Biotech Analyst
Dan Trang – Stonegate Securities
Marcel Wijma, Analyst – The Daily Molecule (Van Leeuwenhoeck Research), Van Leeuwenhoeck Research

The information provided above is from analysts, newsletters and other contributors. Please contact the company and visit its website before making an investment decision.
Investing Highlights
Phase 3 Status from European Regulatory Authority for BETonMACE Clinical Trial
Combination Licensing and Equity Arrangement with China-Based Shenzhen Hepalink Pharmaceutical Co., Ltd.
Two Patents for RVX-208 in China
catalyst Calendar